| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.26B | 9.38 | 67 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 692.99M | 4.09 | 10.76 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 932.87M | 2.35 | -1.84 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 630.68M | 8.04 | -2.62 | -117.82% | 0.18 | |||
| IMNMImmunome, Inc. | 2.22B | 20.14 | -4.03 | -35.5% | -23.01% | -84.4% | 0.03 | |
| NKTRNektar Therapeutics | 744.1M | 36.58 | -4.21 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IBRXImmunityBio, Inc. | 2.78B | 2.82 | -4.55 | 22.71% | -422.28% | |||
| CRVSCorvus Pharmaceuticals, Inc. | 485.43M | 6.50 | -6.37 | -21.01% | 0.03 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 23.65M | 25.67M | 30.11M | 36.48M | 144.23M | 249.43M | 247.77M |
| Revenue Growth % | - | 0.09% | 0.17% | 0.21% | 2.95% | 0.73% | -0.01% |
| Cost of Goods Sold | 0 | 99.99M | 74.81M | 0 | 5.29M | 1.04M | 8.39M |
| COGS % of Revenue | - | 3.9% | 2.48% | - | 0.04% | 0% | 0.03% |
| Gross Profit | 23.65M | -74.32M | -44.7M | 36.48M | 138.94M | 248.39M | 239.38M |
| Gross Margin % | 1% | -2.9% | -1.48% | 1% | 0.96% | 1% | 0.97% |
| Gross Profit Growth % | - | -4.14% | 0.4% | 1.82% | 2.81% | 0.79% | -0.04% |
| Operating Expenses | 117.73M | 44M | 41.5M | 211.07M | 181.71M | 308.04M | 295.66M |
| OpEx % of Revenue | 4.98% | 1.71% | 1.38% | 5.79% | 1.26% | 1.23% | 1.19% |
| Selling, General & Admin | 34.16M | 44.18M | 45.74M | 110.82M | 0 | 144.5M | 0 |
| SG&A % of Revenue | 1.44% | 1.72% | 1.52% | 3.04% | - | 0.58% | - |
| Research & Development | 83.58M | 99.99M | 74.81M | 100.25M | 84.31M | 163.54M | 177.44M |
| R&D % of Revenue | 3.53% | 3.9% | 2.48% | 2.75% | 0.58% | 0.66% | 0.72% |
| Other Operating Expenses | 0 | -100.18M | -79.05M | 0 | 97.4M | 0 | 118.22M |
| Operating Income | -93.45M | -118.32M | -86.19M | -174.59M | -42.77M | -59.65M | -56.28M |
| Operating Margin % | -3.95% | -4.61% | -2.86% | -4.79% | -0.3% | -0.24% | -0.23% |
| Operating Income Growth % | - | -0.27% | 0.27% | -1.03% | 0.76% | -0.39% | 0.06% |
| EBITDA | -86.75M | -111.56M | -79.75M | -167M | -38.36M | -55.56M | -52.92M |
| EBITDA Margin % | -3.67% | -4.35% | -2.65% | -4.58% | -0.27% | -0.22% | -0.21% |
| EBITDA Growth % | - | -0.29% | 0.29% | -1.09% | 0.77% | -0.45% | 0.05% |
| D&A (Non-Cash Add-back) | 6.71M | 6.76M | 6.45M | 7.59M | 4.41M | 4.09M | 3.36M |
| EBIT | -87.34M | -118.32M | -88.83M | -174.31M | -42.77M | -55.74M | -41.86M |
| Net Interest Income | -20K | -2.4M | -2.4M | -5.51M | -1.65M | 12.83M | 6.77M |
| Interest Income | 822K | 1.4M | 706K | 65K | 3.76M | 17.99M | 25.62M |
| Interest Expense | 842K | 3.8M | 3.11M | 5.57M | 5.41M | 5.15M | 18.84M |
| Other Income/Expense | 5.28M | 36.65M | -1.17M | -5.29M | 8.95M | -1.24M | 14M |
| Pretax Income | -88.18M | -81.67M | -87.36M | -179.88M | -33.82M | -60.89M | -42.28M |
| Pretax Margin % | -3.73% | -3.18% | -2.9% | -4.93% | -0.23% | -0.24% | -0.17% |
| Income Tax | -16.55M | 22.26M | -13.27M | 150K | 9.65M | -5.6M | -1.48M |
| Effective Tax Rate % | 0.81% | 1.27% | 0.85% | 1% | 1.29% | 0.91% | 0.97% |
| Net Income | -71.63M | -103.93M | -74.09M | -180.03M | -43.46M | -55.29M | -40.81M |
| Net Margin % | -3.03% | -4.05% | -2.46% | -4.93% | -0.3% | -0.22% | -0.16% |
| Net Income Growth % | - | -0.45% | 0.29% | -1.43% | 0.76% | -0.27% | 0.26% |
| Net Income (Continuing) | -71.63M | -103.93M | -74.09M | -180.03M | -43.46M | -55.29M | -40.81M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.62 | -3.81 | -2.33 | -3.00 | -0.95 | -1.13 | -1.02 |
| EPS Growth % | - | -0.45% | 0.39% | -0.29% | 0.68% | -0.19% | 0.1% |
| EPS (Basic) | -2.62 | -3.81 | -2.33 | -3.13 | -0.95 | -1.13 | -1.02 |
| Diluted Shares Outstanding | 27.31M | 27.31M | 31.78M | 43.86M | 45.71M | 48.89M | 49.99M |
| Basic Shares Outstanding | 27.31M | 27.31M | 31.78M | 42.49M | 45.71M | 48.89M | 49.99M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 171.18M | 164.64M | 152.93M | 354.58M | 473.98M | 528.82M | 929.86M |
| Cash & Short-Term Investments | 124.39M | 97.99M | 176.78M | 321.06M | 402.47M | 442.63M | 820.38M |
| Cash Only | 124.39M | 97.99M | 176.78M | 321.06M | 402.47M | 442.63M | 455.73M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 364.64M |
| Accounts Receivable | 46.08M | 66.3M | 2.05M | 33.52M | 57.08M | 61.44M | 83.1M |
| Days Sales Outstanding | 711 | 942.79 | 24.86 | 335.4 | 144.45 | 89.9 | 122.41 |
| Inventory | -7.57M | 0 | -6.51M | 0 | 692K | 4.5M | 5.45M |
| Days Inventory Outstanding | - | - | - | - | 47.71 | 1.58K | 236.97 |
| Other Current Assets | 42.42M | 352.38K | -25.9M | -7.69M | 3.62M | 9.71M | 7.9M |
| Total Non-Current Assets | 24.6M | 81.3M | 44.26M | 52.7M | 52.78M | 68.18M | 79.64M |
| Property, Plant & Equipment | 20.87M | 72.7M | 36.85M | 42.56M | 38.78M | 42.73M | 47.73M |
| Fixed Asset Turnover | 1.13x | 0.35x | 0.82x | 0.86x | 3.72x | 5.84x | 5.19x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 318K | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 973K | 222.69K | 137K | 0 | 0 |
| Other Non-Current Assets | 2.53M | 6.6M | 4.21M | 6.44M | 8.34M | 14.47M | 17.12M |
| Total Assets | 195.78M | 245.94M | 197.19M | 407.28M | 526.76M | 597M | 1.01B |
| Asset Turnover | 0.12x | 0.10x | 0.15x | 0.09x | 0.27x | 0.42x | 0.25x |
| Asset Growth % | - | 0.26% | -0.2% | 1.07% | 0.29% | 0.13% | 0.69% |
| Total Current Liabilities | 49.61M | 111.96M | 55M | 82.57M | 100.83M | 139.02M | 212.18M |
| Accounts Payable | 6.44M | 20.84M | 7.88M | 10.12M | 14.45M | 17.8M | 25.1M |
| Days Payables Outstanding | - | 76.06 | 38.45 | - | 996.23 | 6.26K | 1.09K |
| Short-Term Debt | 0 | 27.96M | 9.84M | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 1000K | 1000K | 1000K | 1000K | 0 | 0 |
| Other Current Liabilities | 29.91M | 25.28M | -19.8M | 83.68K | 9.15M | 11.6M | 13.1M |
| Current Ratio | 3.45x | 1.47x | 2.78x | 4.29x | 4.70x | 3.80x | 4.38x |
| Quick Ratio | 3.60x | 1.47x | 2.90x | 4.29x | 4.69x | 3.77x | 4.36x |
| Cash Conversion Cycle | - | - | - | - | -804.07 | -4.59K | -732.79 |
| Total Non-Current Liabilities | 89.59M | 114.41M | 86.85M | 93.19M | 87.02M | 89.14M | 436.61M |
| Long-Term Debt | 18.88M | 0 | 36.65M | 50.24M | 47.81M | 48.01M | 391.01M |
| Capital Lease Obligations | 0 | 50.74M | 25.19M | 34.22M | 31.76M | 34.63M | 40.16M |
| Deferred Tax Liabilities | 0 | 0 | -24.87M | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 70.71M | 139.1K | 25.01M | 76.93K | 2.21M | 978K | 0 |
| Total Liabilities | 139.19M | 226.37M | 141.85M | 175.76M | 187.86M | 228.16M | 648.79M |
| Total Debt | 18.88M | 78.7M | 74.47M | 86.16M | 81.45M | 84.03M | 432.72M |
| Net Debt | -105.51M | -19.29M | -102.31M | -234.9M | -321.02M | -358.59M | -23.01M |
| Debt / Equity | 0.33x | 4.02x | 1.35x | 0.37x | 0.24x | 0.23x | 1.20x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | -110.99x | -31.17x | -27.72x | -31.33x | -7.91x | -11.57x | -2.99x |
| Total Equity | 56.58M | 19.57M | 55.35M | 231.53M | 338.9M | 368.84M | 360.72M |
| Equity Growth % | - | -0.65% | 1.83% | 3.18% | 0.46% | 0.09% | -0.02% |
| Book Value per Share | 2.07 | 0.72 | 1.74 | 5.28 | 7.41 | 7.54 | 7.22 |
| Total Shareholders' Equity | 56.58M | 19.57M | 55.35M | 231.53M | 338.9M | 368.84M | 360.72M |
| Common Stock | 0 | 0 | 64K | 118.77K | 129K | 105.11K | 135K |
| Retained Earnings | -175.18M | -369.75M | -349.87M | -649.7M | -689.39M | -744.67M | -795.76M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 67K | 14.08M | 405.15M | 521.31M | -54.67M | -36.26M | -33.76M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -16.63M | -101.38M | -60.57M | -143.11M | -49.21M | 2.94M | 26.06M |
| Operating CF Margin % | -0.7% | -3.95% | -2.01% | -3.92% | -0.34% | 0.01% | 0.11% |
| Operating CF Growth % | - | -5.1% | 0.4% | -1.36% | 0.66% | 1.06% | 7.86% |
| Net Income | -71.63M | -103.93M | -74.09M | -180.03M | -52.54M | -43.37M | -51.09M |
| Depreciation & Amortization | 6.71M | 9.21M | 8.98M | 7.59M | 5.33M | 4.09M | 4.2M |
| Stock-Based Compensation | 666K | 3.06M | 8.16M | 48.89M | 32.89M | 32.47M | 34.19M |
| Deferred Taxes | -16.55M | -22.26M | -13.27M | -12.69M | -3.53M | 0 | 0 |
| Other Non-Cash Items | -3.4M | 22.64M | 38.45M | 15.09M | -7.19M | 3.97M | -6.38M |
| Working Capital Changes | 67.58M | -10.09M | -28.8M | -21.96M | -24.16M | 5.78M | 45.13M |
| Change in Receivables | 0 | 1.83M | -532K | -4.86M | -26.26M | -17.87M | -12.35M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 1.47M | 4.91M | 2.63M | 7.27M |
| Cash from Investing | 58.01M | -4.14M | 467K | -1.28M | -2.2M | -5.42M | -355.13M |
| Capital Expenditures | -3.54M | -4.28M | -3.07M | -1.39M | -2.2M | -4.26M | -5.17M |
| CapEx % of Revenue | 0.15% | 0.17% | 0.1% | 0.04% | 0.02% | 0.02% | 0.02% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 34.1M | 139K | 3.54M | 106K | 6K | -1.17M | 44K |
| Cash from Financing | 101K | 55.13M | 115.94M | 288.19M | 145.44M | 34.35M | 343.88M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 101K | -711K | -42.6M | 1.3M | 5.93M | 34.35M | -8.62M |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -20.16M | -105.65M | -63.65M | -144.49M | -51.41M | -2.48M | 20.89M |
| FCF Margin % | -0.85% | -4.12% | -2.11% | -3.96% | -0.36% | -0.01% | 0.08% |
| FCF Growth % | - | -4.24% | 0.4% | -1.27% | 0.64% | 0.95% | 9.41% |
| FCF per Share | -0.74 | -3.87 | -2.00 | -3.29 | -1.12 | -0.05 | 0.42 |
| FCF Conversion (FCF/Net Income) | 0.23x | 0.98x | 0.82x | 0.79x | 1.13x | -0.05x | -0.64x |
| Interest Paid | 0 | 0 | 0 | 5.71M | 4.48M | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 765K | 977K | 510K |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -126.59% | -272.96% | -197.81% | -125.51% | -15.24% | -15.62% | -11.19% |
| Return on Invested Capital (ROIC) | - | -31597.28% | - | - | -442.43% | -318.08% | -24.26% |
| Gross Margin | 100% | -289.54% | -148.42% | 100% | 96.33% | 99.58% | 96.61% |
| Net Margin | -302.82% | -404.89% | -246.04% | -493.45% | -30.13% | -22.17% | -16.47% |
| Debt / Equity | 0.33x | 4.02x | 1.35x | 0.37x | 0.24x | 0.23x | 1.20x |
| Interest Coverage | -110.99x | -31.17x | -27.72x | -31.33x | -7.91x | -11.57x | -2.99x |
| FCF Conversion | 0.23x | 0.98x | 0.82x | 0.79x | 1.13x | -0.05x | -0.64x |
| Revenue Growth | - | 8.52% | 17.32% | 21.15% | 295.34% | 72.93% | -0.66% |
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Sale of Therapies | - | - | - | - | 309.99M |
| Sale of Therapies Growth | - | - | - | - | - |
| Collaboration Revenue | - | - | - | - | 213K |
| Collaboration Revenue Growth | - | - | - | - | - |
| UNITED STATES | - | 174.27M | - | 169.79M | - |
| UNITED STATES Growth | - | - | - | - | - |
| Europe | - | 3.01M | - | 67.63M | - |
| Europe Growth | - | - | - | - | - |
| International | - | - | - | 3.6M | - |
| International Growth | - | - | - | - | - |
| Genentech | 20.24M | - | 19.57M | - | - |
| Genentech Growth | - | - | - | - | - |
| Eli Lilly | 3.52M | - | 7.36M | - | - |
| Eli Lilly Growth | - | - | - | - | - |
| UK | - | 6.08M | - | - | - |
| UK Growth | - | - | - | - | - |
| GlaxoSmithKline | 6.36M | - | - | - | - |
| GlaxoSmithKline Growth | - | - | - | - | - |
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| UNITED STATES | - | 174.27M | 80.45M | 169.79M | - |
| UNITED STATES Growth | - | - | -53.84% | 111.06% | - |
| Europe | - | 3.01M | 35.49M | 67.63M | - |
| Europe Growth | - | - | 1079.07% | 90.56% | - |
| International | - | - | - | 3.6M | - |
| International Growth | - | - | - | - | - |
| World | - | - | 871K | - | - |
| World Growth | - | - | - | - | - |
| UK | 6.36M | 6.08M | - | - | - |
| UK Growth | - | -4.30% | - | - | - |
| United States | 23.76M | - | - | - | - |
| United States Growth | - | - | - | - | - |
Immunocore Holdings plc (IMCR) reported $379.6M in revenue for fiscal year 2024. This represents a 1505% increase from $23.7M in 2018.
Immunocore Holdings plc (IMCR) saw revenue decline by 0.7% over the past year.
Immunocore Holdings plc (IMCR) reported a net loss of $28.3M for fiscal year 2024.
Immunocore Holdings plc (IMCR) has a return on equity (ROE) of -11.2%. Negative ROE indicates the company is unprofitable.
Immunocore Holdings plc (IMCR) generated $2.9M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.